Based on promising preclinical data, researchers hope to begin clinically testing PLK1-targeted treatments in young people with fibrolamellar carcinoma.

The firm will test CAP-002 in a Phase I/IIa trial involving patients with syntaxin-binding protein 1 developmental and epileptic encephalopathy.

Having established improved cancer detection, the interval cancer rate will reveal whether AI catches certain early cancers missed by standard screening.

Researchers found the therapy downregulated VEGF expression and improved retinal thickness in neovascular age-related macular degeneration patients.

NEW YORK – Erasca said on Tuesday it is prioritizing development of its recently acquired preclinical RAS programs, pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001, and will be ...

The funds will support multiple new and ongoing clinical trials of Tilt's oncolytic adenoviral therapy TILT-123.